A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Tetsuo Tani(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Keiko Ohgino(Keio University), Aoi Kuroda(Keio University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Kouta Ishioka(Keio University), Kenzo Soejima(Keio University), Katsuhiko Naoki(Broad Institute), Makoto Nishino(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101